$SNY

China's diabetes device market projected to nearly double from $7.19B in 2025 to $14.51B by 2034, driven by 118M patients and healthcare reforms.

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.

Sanofi and Regeneron win EU approval for Dupixent as first targeted therapy for chronic urticaria in children ages 2-11, expanding the blockbuster drug's market reach.

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.

Biogen partners with Alloy Therapeutics to advance antisense oligonucleotide therapies using the AntiClastic platform for multiple undisclosed disease indications.

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.

Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.

European Commission approves Sanofi's Rezurock for chronic GvHD treatment in patients 12+, based on 74% response rate from Phase 2 trials.

AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.

NodThera, a clinical-stage NLRP3 inhibitor biotech, will present at major April 2026 investor conferences including Piper Sandler and Needham.

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.